US Broker Ratings

Immatics N.V. (IMTX) Stock Analysis: Potential 68% Upside Amid Strategic Collaborations and Innovative Cancer Therapies

Immatics N.V. (NASDAQ: IMTX), a promising player in the biotechnology sector, is capturing investor attention with its cutting-edge approach to cancer treatment. Headquartered in Tübingen, Germany, this clinical-stage biopharmaceutical company..

Rocket Pharmaceuticals (RCKT) Investor Outlook: Exploring a 140.90% Potential Upside in Genetic Therapies

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a promising player in the biotechnology sector, leveraging cutting-edge genetic therapies aimed at treating rare and devastating diseases. With a current market capitalization of..

HealthStream, Inc. (HSTM) Stock Analysis: Unveiling a 35.94% Potential Upside in Health Information Services

HealthStream, Inc. (NASDAQ: HSTM), a prominent player in the health information services industry, presents an intriguing opportunity for investors looking for growth in the healthcare sector. With a market capitalization..

Fulgent Genetics, Inc. (FLGT) Stock Analysis: Navigating a 22% Potential Upside Amidst a Challenging Landscape

Fulgent Genetics, Inc. (NASDAQ: FLGT), a prominent player in the healthcare sector specializing in diagnostics and research, offers a mixed bag of opportunities and challenges for investors. Currently trading at..

AnaptysBio, Inc. (ANAB) Stock Analysis: Unpacking a 21.51% Upside Potential Amid Robust Revenue Growth

AnaptysBio, Inc. (NASDAQ: ANAB) is a clinical-stage biotechnology company that has caught the attention of investors with its focus on delivering cutting-edge immunology therapeutics for autoimmune and inflammatory diseases. With..

Bicara Therapeutics Inc. (BCAX) Investor Outlook: Exploring a 32% Potential Upside in Biotech Innovation

Bicara Therapeutics Inc. (NASDAQ: BCAX), a promising player in the biotechnology sector, is garnering attention from investors eager to explore the potential of its innovative bifunctional therapies for solid tumors...

Cogent Biosciences, Inc. (COGT): Investor Outlook on a Biotech Gem with 55% Upside Potential

Cogent Biosciences, Inc. (NASDAQ: COGT) stands out in the biotechnology sector, attracting investor attention with a compelling growth narrative and a promising pipeline of precision therapies. Headquartered in Waltham, Massachusetts,..

uniQure N.V. (QURE) Stock Analysis: A Potential Upside of 64% Amidst Promising Gene Therapy Innovations

For investors eyeing the healthcare sector, specifically the burgeoning field of biotechnology, uniQure N.V. (QURE) presents an intriguing opportunity. With a market capitalization of $1.52 billion, this Netherlands-based company is..

Savara, Inc. (SVRA) Stock Analysis: A Biotech Gem with Over 109% Potential Upside

Savara, Inc. (NASDAQ: SVRA) is capturing attention in the healthcare sector, particularly within the biotechnology industry, due to its promising market potential. With a market capitalization of $1.06 billion, Savara..

RxSight, Inc. (RXST) Stock Analysis: Unveiling a Potential 66% Upside Amidst Market Challenges

RxSight, Inc. (NASDAQ: RXST), a pioneering player in the medical devices sector, is garnering attention from investors due to its innovative approach to cataract surgery. The company specializes in light..

CorMedix Inc. (CRMD) Stock Analysis: Uncovering an 89% Potential Upside in the Biotech Sector

Investors looking for a compelling opportunity in the healthcare sector should turn their attention to CorMedix Inc. (NASDAQ: CRMD). This biopharmaceutical company, headquartered in Parsippany, New Jersey, is primarily focused..

LENZ Therapeutics, Inc. (LENZ) Stock Analysis: Exploring a 307% Potential Upside in a Promising Biotech

For investors with an eye on the biotechnology sector, LENZ Therapeutics, Inc. (NASDAQ: LENZ) presents a compelling opportunity. With a substantial market capitalization of $304.76 million, this California-based company is..

Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring a 605% Upside Potential

Investors with an eye on the biotech sector might find Anavex Life Sciences Corp. (NASDAQ: AVXL) an intriguing opportunity, especially considering its substantial potential upside of over 605%. With a..

Enliven Therapeutics, Inc. (ELVN)

❌ Error generating article: Server error: `POST https://api.openai.com/v1/chat/completions` resulted in a `502 Bad Gateway` response: error code: 502

..

CareDx, Inc. (CDNA) Stock Analysis: Exploring 20% Upside Potential in the Transplant Diagnostics Sector

CareDx, Inc. (NASDAQ: CDNA) is a prominent player in the healthcare sector, specializing in diagnostics and research with a core focus on solutions that enhance outcomes for transplant patients. Headquartered..

SI-BONE, Inc. (SIBN) Stock Analysis: Exploring Nearly 97% Upside Potential with Strong Buy Ratings

SI-BONE, Inc. (NASDAQ: SIBN), a prominent player in the healthcare sector, specifically within the medical devices industry, is garnering significant attention from investors. Based in Santa Clara, California, this innovative..

Spyre Therapeutics, Inc. (SYRE): Analyst Ratings Suggest a Promising 28.77% Potential Upside

Spyre Therapeutics, Inc. (NASDAQ: SYRE) is making waves in the biotechnology sector, particularly among investors looking for high-growth potential in the healthcare arena. As a clinical-stage biotech firm, Spyre Therapeutics..

Cronos Group Inc. (CRON) Stock Analysis: Evaluating a 47% Revenue Growth Amidst Market Challenges

Cronos Group Inc. (NASDAQ: CRON) is a prominent player in the healthcare sector, specializing in the cultivation and distribution of cannabis products. As individual investors consider the potential of this..

Nurix Therapeutics, Inc. (NRIX) Stock Analysis: A Biotech with High Potential Upside and Strong Analyst Confidence

Nurix Therapeutics, Inc. (NASDAQ: NRIX) stands out in the biotechnology sector as a company with a compelling narrative and significant growth potential. Headquartered in Brisbane, California, Nurix is a clinical-stage..

Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Exploring a 68% Upside Potential in the Healthcare Sector

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a dynamic player in the healthcare sector, offers enticing prospects for investors keen on the biopharmaceutical landscape. With a market capitalization of $1.14 billion,..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds